+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Aeterna Zentaris Inc (AEZS) - Financial and Strategic SWOT Analysis Review

Aeterna Zentaris Inc (AEZS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of unmet medical needs. The company’s lead product, Macrilen (macimorelin), a ghrelin receptor agonist and the orally active small molecule is used for the treatment of patients with adult growth hormone deficiency (AGHD). The company has operations in the US, Canada, and Germany and has license agreements for its products in Ireland, China, the British Virgin Islands, Denmark, and other countries. Aeterna Zentaris is headquartered in Summerville, South Carolina, the US.

Aeterna Zentaris Inc Key Recent Developments

Nov 03, 2022: Aeterna Zentaris Reports Third Quarter 2022 Financial Results
Aug 03, 2022: Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
Jul 18, 2022: Aeterna Zentaris Announces Effective Date of Share Consolidation
Jul 15, 2022: Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
Jun 21, 2022: Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Aeterna Zentaris Inc - Key Facts
  • Aeterna Zentaris Inc - Key Employees
  • Aeterna Zentaris Inc - Key Employee Biographies
  • Aeterna Zentaris Inc - Major Products and Services
  • Aeterna Zentaris Inc - History
  • Aeterna Zentaris Inc - Company Statement
  • Aeterna Zentaris Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Aeterna Zentaris Inc - Business Description
  • Product Category: License Fee
  • Performance
  • Product Category: Product Sales
  • Performance
  • Product Category: Royalty Income
  • Performance
  • Product Category: Supply Chain
  • Performance
  • Geographical Segment: Denmark
  • Performance
  • Geographical Segment: Ireland
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: Switzerland
  • Performance
  • R&D Overview
  • Aeterna Zentaris Inc - Corporate Strategy
  • Aeterna Zentaris Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Aeterna Zentaris Inc - Strengths
  • Aeterna Zentaris Inc - Weaknesses
  • Aeterna Zentaris Inc - Opportunities
  • Aeterna Zentaris Inc - Threats
  • Aeterna Zentaris Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Aeterna Zentaris Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 03, 2022: Aeterna Zentaris Reports Third Quarter 2022 Financial Results
  • Aug 03, 2022: Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
  • Jun 21, 2022: Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
  • May 16, 2022: Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
  • May 11, 2022: Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
  • Apr 12, 2022: Aeterna Zentaris to participate at the virtual investor 2022 CEO Spotlight
  • Mar 29, 2022: Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
  • Mar 10, 2022: Aeterna Zentaris announces expansion of research program with Julius-Maximilians-University Wuerzburg aiming to accelerate development of vaccine programs
  • Jan 26, 2022: Aeterna Zentaris provides business outlook and outlines pipeline priorities
  • Dec 23, 2021: Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Aeterna Zentaris Inc, Key Facts
  • Aeterna Zentaris Inc, Key Employees
  • Aeterna Zentaris Inc, Key Employee Biographies
  • Aeterna Zentaris Inc, Major Products and Services
  • Aeterna Zentaris Inc, History
  • Aeterna Zentaris Inc, Subsidiaries
  • Aeterna Zentaris Inc, Key Competitors
  • Aeterna Zentaris Inc, Annual Ratios
  • Aeterna Zentaris Inc, Interim Ratios
  • Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Aeterna Zentaris Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Aeterna Zentaris Inc, Performance Chart (2017 - 2021)
  • Aeterna Zentaris Inc, Ratio Charts
  • Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Lumos Pharma Inc
  • Pfizer Inc
  • Lumos Pharma Inc
  • Pfizer Inc
  • Theratechnologies Inc
  • Ipsen Biopharmaceuticals Inc
  • Eli Lilly and Co
  • Ipsen Biopharmaceuticals Inc
  • Eli Lilly and Co
  • Theratechnologies Inc
  • Novo Nordisk Inc